MX2020007434A - Stabilized pharmaceutical formulation comprising everolimus. - Google Patents

Stabilized pharmaceutical formulation comprising everolimus.

Info

Publication number
MX2020007434A
MX2020007434A MX2020007434A MX2020007434A MX2020007434A MX 2020007434 A MX2020007434 A MX 2020007434A MX 2020007434 A MX2020007434 A MX 2020007434A MX 2020007434 A MX2020007434 A MX 2020007434A MX 2020007434 A MX2020007434 A MX 2020007434A
Authority
MX
Mexico
Prior art keywords
everolimus
pharmaceutical formulation
stabilized pharmaceutical
butylhydroxytoluene
granules
Prior art date
Application number
MX2020007434A
Other languages
Spanish (es)
Inventor
Jong Lae Lim
Kyung Hee Han
Min Soo Kim
Shin Jung Park
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2020007434A publication Critical patent/MX2020007434A/en

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41A—FUNCTIONAL FEATURES OR DETAILS COMMON TO BOTH SMALLARMS AND ORDNANCE, e.g. CANNONS; MOUNTINGS FOR SMALLARMS OR ORDNANCE
    • F41A17/00—Safety arrangements, e.g. safeties
    • F41A17/42—Safeties for locking the breech-block or bolt in a safety position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present invention relates to a stabilized pharmaceutical formulation comprising everolimus. Specifically, the present invention relates to a pharmaceutical formulation comprising granules comprising everolimus as an active ingredient and butylhydroxytoluene as an antioxidant. Further, the present invention relates to a method for preparing a pharmaceutical formulation comprising everolimus as an active ingredient and butylhydroxytoluene as an antioxidant, comprising the steps of: dissolving everolimus, butylhydroxytoluene and binder(s), and preparing a mixture; preparing granules from the mixture; and adding a lubricant into the granules to prepare a granule mixture.
MX2020007434A 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus. MX2020007434A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180004458A KR102051806B1 (en) 2018-01-12 2018-01-12 Stabilized pharmaceutical formulation comprising Everolimus
PCT/KR2019/000204 WO2019139313A1 (en) 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus

Publications (1)

Publication Number Publication Date
MX2020007434A true MX2020007434A (en) 2022-04-27

Family

ID=67219083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007434A MX2020007434A (en) 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus.

Country Status (7)

Country Link
JP (1) JP7218372B2 (en)
KR (1) KR102051806B1 (en)
CN (1) CN111565714B (en)
BR (1) BR112020014292A2 (en)
EA (1) EA202091455A1 (en)
MX (1) MX2020007434A (en)
WO (1) WO2019139313A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111388455B (en) * 2020-04-09 2022-09-02 沈阳药科大学 Everolimus oral film and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
DK2365802T3 (en) * 2008-11-11 2017-11-13 Univ Texas RAPAMYCINE MICROCAPLES AND USE FOR CANCER TREATMENT
PE20141649A1 (en) * 2011-10-06 2014-11-14 Novartis Ag PHARMACEUTICAL COMPOSITIONS INCLUDING 40-O- (2-HYDROXY) ETHYL-RAPAMYCIN
KR20140032586A (en) * 2012-09-06 2014-03-17 한국원자력의학원 A pharmaceutical composition for radiation therapy of egfr-tki-resistant lung cancer caused by pten function deficiency
TW201503912A (en) * 2013-03-19 2015-02-01 Novartis Ag Pharmaceutical compositions comprising everolimus
MX367121B (en) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Stable solid composition of immunosuppressants.
KR20150138104A (en) * 2014-05-30 2015-12-09 동아에스티 주식회사 Pharmaceutical preperation containing Bepotastine and Glyceryl Behenate
CN104398483B (en) * 2014-11-05 2018-01-26 上海医药集团青岛国风药业股份有限公司 A kind of olmesartan medoxomil tablet and its preparation technology
CN105106145A (en) * 2015-08-27 2015-12-02 济川药业集团有限公司 Everolimus tablet and preparation method thereof
EP3345601A4 (en) * 2015-09-03 2019-05-15 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition containing rapamycin or derivative thereof
JP2018111662A (en) * 2017-01-12 2018-07-19 ニプロ株式会社 Everolimus pharmaceutical preparation

Also Published As

Publication number Publication date
WO2019139313A1 (en) 2019-07-18
CN111565714B (en) 2022-05-17
JP7218372B2 (en) 2023-02-06
CN111565714A (en) 2020-08-21
KR102051806B1 (en) 2019-12-04
BR112020014292A2 (en) 2020-12-08
KR20190086212A (en) 2019-07-22
JP2021510374A (en) 2021-04-22
EA202091455A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018500975A1 (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
EP4269440A3 (en) Composition for treating il-6-related diseases
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190561A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2016012668A (en) SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a</ i>][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2019012454A (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
AU2017262586A1 (en) Improved drug formulations
MX2019008865A (en) Solid preparation comprising tofogliflozin and method for producing same.
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
WO2016126058A3 (en) Solid dispersion containing dutasteride, and composition containing same
MX2020007434A (en) Stabilized pharmaceutical formulation comprising everolimus.
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
PH12017550051A1 (en) A pharmaceutical composition for treating gastrointestinal diseases
EA201991269A1 (en) PREVENTIVE AGENT, AGENT, SUPPRESSING THE BEGINNING OF THE DISEASE, OR THE THERAPEUTIC AGENT FOR PROGRESSIVE IMMUNE DEMIELINIZING DISEASES
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy